CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 198 enrolled
Drug / intervention
MM120 +1 moredrug
Likely dose
Not stated in record
Key inclusion· 5
  • ✓Diagnosis of DSM-5 generalized anxiety disorder
  • ✓Bodyweight ≥50 kg
  • ✓BMI between 18 and 38 kg/m²
  • ✓Ability to swallow capsules
Key exclusion· 5
  • ✕Prior lifetime diagnosis of schizophrenia spectrum, psychotic disorders, or bipolar disorder
  • ✕Significant risk of suicide attempt based on medical history or active suicidal ideation
  • ✕Currently pregnant or breastfeeding, or plan to become pregnant or breastfeed during study
  • ✕Unwillingness or inability to discontinue prohibited concomitant medications, supplements, or other therapeutics

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05407064
NCT05407064Phase 2Completed
CompareCT.gov

A Phase 2, Multi-center, Randomized, Double-Blind, Parallel-Group, Dose-Finding Study to Assess the Effect of Four Doses of MM120 (LSD D-Tartrate) for the Treatment of Anxiety Symptoms

Definium Therapeutics US, Inc.·interventional·Posted Jun 7, 2022·Updated Feb 27, 2026

In Brief

A Phase 2 clinical trial evaluating MM120 and Placebo for Anxiety Generalized. Completed, enrolled 198 participants across 22 sites.

Detailed Summary

This is a Phase 2, multi-center, randomized, double-blind, parallel-group, dose-finding study to assess the effect of 4 doses of MM120 (25, 50, 100 or 200 μg freebase-equivalent) for the treatment of anxiety symptoms in subjects diagnosed with generalized anxiety disorder (GAD).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAnxiety Generalized
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2023202420252026
First PostedJun 7, 2022
Enrollment StartAug 24, 2022
Primary CompletionOct 6, 2023
Study CompletionNov 27, 2023
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 4.1 years ago

Interventions

MM120drug

A psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A).

Placeboother

A substance that is designed to have no therapeutic value.